The Indian Council of Medical Research (ICMR), India’s leading organization for health-related research, has issued a recommendation calling for restrictions on the use of the widely used pain relief and fever-reducing medication, Nimesulide.
The ICMR is specifically advising that Nimesulide should be prohibited for administration to patients under the age of 18, as well as individuals who are 60 years of age or older. This recommendation for a ban stems from concerns regarding the safety profile of the drug within these particular age groups.
The ICMR has further stipulated that all formulations of Nimesulide exceeding a dosage of 100 mg should also be subject to a nationwide ban.
The recommendation focuses on limiting Nimesulide’s use due to potential risks to the health of vulnerable populations.
India’s Nimesulide market, valued at Rs 497 Cr and growing at 11% annually, faces potential disruption from a proposed DTAB ban. Top-selling brands like Dr Reddy’s Nise, Nimulid, Nimtex, and Nicip dominate the anti-inflammatory drug sector with millions of annual prescriptions.
The Indian Council of Medical Research (ICMR) has recommended a ban on Nimesulide for individuals under 18 and over 60 due to safety concerns, particularly liver damage and gastrointestinal issues.
Leave feedback about this